A5021183522- Mast cells and histamine
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Statistical Methods in Clinical Trials
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Attention Deficit Hyperactivity Disorder
- Multiple and Secondary Primary Cancers
- Bladder and Urothelial Cancer Treatments
- Drug-Induced Adverse Reactions
- Autoimmune Bullous Skin Diseases
- Chronic Lymphocytic Leukemia Research
- Prostate Cancer Treatment and Research
- Asthma and respiratory diseases
- Bipolar Disorder and Treatment
- Radiopharmaceutical Chemistry and Applications
Analysis Group (United States)
2021-2023
Abstract Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients AdvSM treated avapritinib in the Phase 1 EXPLORER (NCT0256198) and 2 PATHFINDER (NCT03580655) trials ( N = 176) best available therapy (BAT; 141). A multi-center, observational, retrospective chart review was conducted at six sites (four European, two American) to collect data from who received BAT; these...
BackgroundThe comparative efficacy and health-related quality of life (HRQoL) outcomes nivolumab plus cabozantinib versus pembrolizumab axitinib as first-line treatments for advanced renal cell carcinoma (aRCC) have not been assessed in head-to-head trials.ObjectiveTo assess the HRQoL axitinib.Design, setting, participantsPatient-level data from CheckMate 9ER trial published KEYNOTE-426 were used. reweighted to match key baseline characteristics reported KEYNOTE-426.InterventionNivolumab...
Three novel androgen receptor inhibitors are approved in the USA for treatment of non-metastatic castration-resistant prostate cancer (nmCRPC): apalutamide, enzalutamide, and darolutamide. All three therapies have demonstrated prolonged metastasis-free survival their respective phase III trials, with differing safety profiles. The objective this study was to compare mean per-patient costs all-cause adverse events (AEs) requiring hospitalization between darolutamide versus apalutamide...
e16500 Background: Bladder cancer is the sixth most prevalent malignancy in United States, of which urothelial carcinoma (UC) predominant histologic type. The prognosis metastatic UC (mUC) generally poor with standard platinum-based chemotherapy (PBC) regimens. With approvals immunotherapy (IO) and antibody drug conjugates (ADCs) recent years, treatment landscape has been evolving substantially. This study aimed to describe current, real-world patterns mUC. Methods: retrospective used...
4578 Background: Nivolumab in combination with cabozantinib (N+C) has demonstrated significantly improved progression-free survival (PFS), objective response rate (ORR), and overall (OS), compared sunitinib as a first-line (1L) treatment for aRCC the phase 3 CheckMate (CM) 9ER trial. As there are no head-to-head trials comparing N+C pembrolizumab axitinib (P+A), this study efficacy of P+A 1L aRCC. Methods: An MAIC was conducted using individual patient data on (N = 323) from CM trial (median...